Key Takeaways from the THR-\u03b2 Agonist Market Report<\/b><\/p>\n Discover which indication is expected to grab the major THR-\u03b2 agonist market share @ THR-\u03b2 Agonist Market Report<\/a><\/b><\/p>\n THR-\u03b2 Agonist Market Dynamics<\/b><\/p>\n The THR-\u03b2 agonist market is gaining significant momentum due to the growing prevalence of metabolic and liver diseases<\/b>, particularly MASH and NAFLD. The approval of REZDIFFRA<\/b> by the US FDA in March 2024 as the first THR-\u03b2 agonist for treating adults with noncirrhotic MASH and moderate to advanced fibrosis (F2-F3) has marked a significant milestone in this space. This has created a favorable market environment and is expected to drive further investments and research efforts<\/b> to expand the therapeutic potential of THR-\u03b2 agonists.<\/p>\n Key drivers of the THR-\u03b2 agonist market include the rising global burden of obesity, type 2 diabetes, and metabolic syndromes<\/b>, which are strongly linked to NASH and NAFLD. Increasing awareness of liver health and the demand for targeted, noninvasive therapies<\/b> are boosting interest in THR-\u03b2 agonists as they address the underlying lipid dysregulation rather than just symptomatic management. The drug class has also gained attention for its favorable safety profile compared to traditional NASH treatments, such as pioglitazone or vitamin E. Additionally, advances in biomarker-based patient selection and non-invasive diagnostic tools<\/b> are expected to improve clinical outcomes and accelerate the uptake of THR-\u03b2 therapies.<\/p>\n However, market growth is not without challenges. A key restraint is the limited number of approved drugs<\/b> in this class, with REZDIFFRA being the only FDA-approved THR-\u03b2 agonist so far. High development costs, complex clinical trial designs, and stringent regulatory requirements<\/b> for NASH drugs also pose barriers. Moreover, long-term efficacy and safety data are still being evaluated, and competition from alternative mechanisms of action<\/b>, such as FXR agonists, PPAR modulators, and FGF21 analogs, may impact the market share of THR-\u03b2 agonists.<\/p>\n The competitive landscape is expected to intensify as multiple companies are pursuing THR-\u03b2 agonist candidates. Madrigal Pharmaceuticals, the developer of resmetirom, currently holds a first-mover advantage, but pipeline candidates such as VK2809 (Viking Therapeutics)<\/b> are showing promising results in clinical trials. Collaborations, partnerships, and licensing agreements<\/b> are becoming common strategies for companies to strengthen their foothold in this emerging therapeutic segment.<\/p>\n In the future outlook, the THR-\u03b2 agonist market is poised for strong growth as more drugs reach late-stage trials and potential approvals<\/b>. Expansion of indications beyond MASH could broaden the addressable market. As payer acceptance and reimbursement frameworks<\/b> evolve, the commercial potential of this drug class is expected to improve. Overall, the combination of clinical innovation, unmet medical need, and supportive regulatory momentum will be critical in shaping the dynamics of the THR-\u03b2 agonist market over the next decade.<\/p>\n THR-\u03b2 Agonist Treatment Market<\/b><\/p>\n To date, REZDIFFRA (resmetirom, MGL\u20113196)<\/b> remains the only approved THR\u2011\u03b2 agonist for treating adults with noncirrhotic MASH and moderate to advanced liver fibrosis (F2\u2013F3), in combination with diet and exercise. The US FDA granted REZDIFFRA accelerated approval in March 2024, based on evidence of improvements in MASH and fibrosis, with continued approval contingent upon confirmation of clinical benefits in ongoing studies.<\/p>\n Madrigal is also advancing REZDIFFRA for compensated MASH cirrhosis (stage F4c), currently being assessed in the fully enrolled Phase III MAESTRO-NASH OUTCOMES trial, which is evaluating its effect on preventing liver decompensation events.<\/p>\n In June 2025, REZDIFFRA received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for treating MASH with moderate to advanced fibrosis, supported by Phase III MAESTRO-NASH trial results. A final decision from the European Commission is anticipated by August 2025, which would make REZDIFFRA the first approved therapy for MASH in the EU if granted.<\/p>\n Following European approval, Madrigal plans a phased rollout across Europe, starting with Germany in the second half of 2025, marking the first availability of an authorized treatment for MASH-related liver fibrosis in the region.<\/p>\n In May 2025, Madrigal reported Phase III data showing that REZDIFFRA significantly reduced liver stiffness and the risk of portal hypertension in patients with compensated MASH cirrhosis, with 65% of patients shifting to lower risk categories by the second year of treatment.<\/p>\n Learn more about the THR-\u03b2 agonist\u00a0@ THR-\u03b2 Agonist Analysis<\/a><\/b><\/p>\n Key Emerging THR-\u03b2 Agonist and Companies<\/b><\/p>\n Key emerging THR\u2011\u03b2 agonists such as VK2809 <\/b>(Viking Therapeutics), ALG\u2011055009<\/b> (Aligos Therapeutics), TERN-501<\/b> (Terns Inc.), ECC4703 <\/b>(Eccogene), and VK0214 <\/b>(Viking Therapeutics), among others, are demonstrating therapeutic potential across a range of indications, with efforts focused on expanding treatment options in both metabolic and rare genetic diseases.<\/p>\n VK2809 <\/b>is an orally administered, liver-directed, and subtype-selective THR\u2011beta agonist designed to precisely regulate lipid metabolism. By specifically activating THR\u2011\u03b2 in liver tissue, it stimulates the expression of genes involved in lipid processing and clearance, resulting in improved cholesterol and lipoprotein levels. VK2809 has demonstrated strong therapeutic potential in lipid-related disorders, achieving both primary and secondary endpoints in the Phase IIb VOYAGE trial in patients with biopsy-confirmed NASH\/MASH and fibrosis, as well as in a Phase IIa study in patients with elevated LDL-C and NAFLD.<\/p>\n In June 2024, Viking Therapeutics announced positive 52-week histological outcomes from the Phase IIb VOYAGE trial in biopsy-confirmed NASH patients, reinforcing VK2809’s promise for treating MASH with fibrosis.<\/p>\n ALG\u2011055009<\/b>, developed by Aligos Therapeutics<\/b>, is an oral small-molecule THR\u2011beta agonist under investigation for MASH. Engineered for best-in-class potency and selectivity, it aims to enhance lipid metabolism, promote fatty acid oxidation, and improve bile acid synthesis, with the potential to reverse hepatic steatosis. By selectively activating THR\u2011\u03b2, ALG\u2011055009 reduces systemic lipid levels while avoiding off-target effects related to THR\u2011\u03b1. Aligos Therapeutics is exploring strategies to advance its development, including potential out-licensing.<\/p>\n In November 2024, the company presented positive Phase IIa HERALD trial data on ALG\u2011055009 in MASH patients during a late-breaker oral session at The Liver Meeting 2024 (AASLD). In September 2024, topline Phase IIa HERALD results showed that ALG\u2011055009 met its primary endpoint, achieving significant liver fat reduction at Week 12 as assessed by MRI-PDFF. Preparations for a Phase IIb trial are ongoing, with completion anticipated by mid-2025 and final trial designs under review.<\/p>\n VK0214<\/b>, another novel oral THR\u2011\u03b2 agonist from Viking Therapeutics, is being developed for X-linked adrenoleukodystrophy (X\u2011ALD), particularly the adrenomyeloneuropathy (AMN) form, and has received orphan drug designation from the US FDA. In a placebo-controlled Phase Ib study in adult males with AMN, VK0214 was well-tolerated with once-daily dosing over 28 days and produced significant reductions in plasma very long-chain fatty acids (VLCFAs) and other lipid markers. By upregulating ABCD2 expression, which encodes a compensatory transporter (ALDRP), VK0214 aims to normalize VLCFA metabolism and potentially reduce demyelination, offering a therapeutic approach for all forms of X\u2011ALD, a progressive metabolic disorder with no approved treatments.<\/p>\n In October 2024, Viking reported positive Phase Ib results for VK0214, meeting all primary and secondary endpoints. The therapy was well-tolerated, with most adverse events mild or moderate and one severe event, a wrist fracture, occurring in a placebo recipient.<\/p>\n Earlier, in June 2021, Viking announced positive results from a first-in-human Phase I trial of VK0214, which included single and multiple ascending dose cohorts in healthy volunteers. The study met its safety and efficacy objectives, with no serious adverse events or dose-related safety issues observed.<\/p>\n The anticipated launch of these emerging therapies are poised to transform the THR-\u03b2 agonist market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the THR-\u03b2 agonist market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n To know more about THR-\u03b2 agonist clinical trials, visit @ THR-\u03b2 Agonist Treatment<\/a><\/b><\/p>\n THR-\u03b2 Agonist Overview<\/b><\/p>\n THR\u2011\u03b2, the beta isoform of the thyroid hormone receptor, is a key regulator of lipid metabolism, cholesterol transport, bile acid production, and mitochondrial activity, particularly in the liver. Selective activation of THR\u2011\u03b2 enhances hepatic fat oxidation, reduces inflammation, and suppresses fibrogenic pathways, mechanisms highly relevant to MASH therapy. Furthermore, THR\u2011\u03b2 activation upregulates the ABCD2 gene, which encodes a compensatory peroxisomal transporter, offering therapeutic potential for rare genetic diseases like X\u2011ALD by lowering the accumulation of very long-chain fatty acids.<\/p>\n The therapeutic significance of THR\u2011\u03b2 lies in its ability to provide metabolic benefits without triggering the adverse effects linked to THR\u2011\u03b1 activation, such as cardiac and skeletal toxicity. Novel THR\u2011\u03b2 agonists are being developed to achieve optimal liver targeting and subtype selectivity, to improve liver histology, reverse steatosis, and prevent cirrhosis progression. Current clinical programs aim to validate these benefits through robust long-term safety and efficacy studies, with ongoing trials in both MASH and X\u2011ALD underscoring THR\u2011\u03b2 as a pivotal molecular target in metabolic and rare diseases.<\/p>\n THR-\u03b2 Agonist Epidemiology Segmentation<\/b><\/p>\n The THR-\u03b2 agonist market report proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM, segmented into:<\/p>\n THR-\u03b2 Agonist Report Metrics<\/b><\/p>\n<\/td>\n Details<\/b><\/p>\n<\/td>\n<\/tr>\n Study Period<\/p>\n<\/td>\n 2020\u20132034<\/p>\n<\/td>\n<\/tr>\n THR-\u03b2 Agonist Report\u00a0Coverage<\/p>\n<\/td>\n 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/p>\n<\/td>\n<\/tr>\n Key Indications Covered in the Report<\/p>\n<\/td>\n MASH, X-linked Adrenoleukodystrophy (X-ALD), and others<\/p>\n<\/td>\n<\/tr>\n Key THR-\u03b2 Agonist Companies<\/p>\n<\/td>\n Viking Therapeutics, Aligos Therapeutics, Terns Inc., Eccogene, Madrigal Pharmaceuticals, and others<\/p>\n<\/td>\n<\/tr>\n Key THR-\u03b2 Agonist<\/p>\n<\/td>\n VK2809, ALG\u2011055009, TERN-501, ECC4703, VK0214, REZDIFFRA, and others<\/p>\n<\/td>\n<\/tr>\n Scope of the <\/b>THR-\u03b2 Agonist<\/b>\u00a0Market Report<\/b><\/p>\n Discover more about THR-\u03b2 agonist in development @ THR-\u03b2 Agonist Clinical Trials<\/a><\/b><\/p>\n Table of Contents<\/b><\/p>\n 1<\/p>\n<\/td>\n Key Insights<\/p>\n<\/td>\n<\/tr>\n 2<\/p>\n<\/td>\n Report Introduction<\/p>\n<\/td>\n<\/tr>\n 3<\/p>\n<\/td>\n Executive Summary<\/p>\n<\/td>\n<\/tr>\n 4<\/p>\n<\/td>\n Key Events<\/p>\n<\/td>\n<\/tr>\n 5<\/p>\n<\/td>\n Market Forecast Methodology<\/p>\n<\/td>\n<\/tr>\n 6<\/p>\n<\/td>\n THR-\u03b2 Agonist Market Overview at a Glance in the 7MM<\/p>\n<\/td>\n<\/tr>\n 6.1<\/p>\n<\/td>\n Market Share (%) Distribution by Indications in 2024<\/p>\n<\/td>\n<\/tr>\n 6.2<\/p>\n<\/td>\n Market Share (%) Distribution by Indications in 2034<\/p>\n<\/td>\n<\/tr>\n 7<\/p>\n<\/td>\n THR-\u03b2 Agonist: Background and Overview<\/p>\n<\/td>\n<\/tr>\n 7.1<\/p>\n<\/td>\n Introduction<\/p>\n<\/td>\n<\/tr>\n 7.2<\/p>\n<\/td>\n Evolution of THR-\u03b2 Agonist<\/p>\n<\/td>\n<\/tr>\n 7.3<\/p>\n<\/td>\n Treatment<\/p>\n<\/td>\n<\/tr>\n 8<\/p>\n<\/td>\n Target Patient Pool<\/p>\n<\/td>\n<\/tr>\n 8.1<\/p>\n<\/td>\n Key Findings<\/p>\n<\/td>\n<\/tr>\n 8.2<\/p>\n<\/td>\n Assumptions and Rationale: 7MM<\/p>\n<\/td>\n<\/tr>\n 8.3<\/p>\n<\/td>\n Epidemiology Scenario in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.3.1<\/p>\n<\/td>\n Total Cases in Selected Indications for THR-\u03b2 Agonist in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.3.2<\/p>\n<\/td>\n Total Eligible Patient Pool in Selected Indications for THR-\u03b2 Agonist in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.3.3<\/p>\n<\/td>\n Total Treated Cases in Selected Indications for THR-\u03b2 Agonist in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.4<\/p>\n<\/td>\n The US<\/p>\n<\/td>\n<\/tr>\n 8.5<\/p>\n<\/td>\n EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 8.6<\/p>\n<\/td>\n Japan<\/p>\n<\/td>\n<\/tr>\n 9<\/p>\n<\/td>\n Marketed Therapies<\/p>\n<\/td>\n<\/tr>\n 9.1<\/p>\n<\/td>\n Key Cross Competition<\/p>\n<\/td>\n<\/tr>\n 9.2<\/p>\n<\/td>\n REZDIFFRA (resmetirom, MGL\u20113196): Madrigal Pharmaceuticals<\/p>\n<\/td>\n<\/tr>\n 9.2.1<\/p>\n<\/td>\n Product Description<\/p>\n<\/td>\n<\/tr>\n 9.2.2<\/p>\n<\/td>\n Regulatory Milestones<\/p>\n<\/td>\n<\/tr>\n 9.2.3<\/p>\n<\/td>\n Others Developmental Activities<\/p>\n<\/td>\n<\/tr>\n 9.2.4<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n 9.2.5<\/p>\n<\/td>\n Safety and Efficacy<\/p>\n<\/td>\n<\/tr>\n List of drugs to be continued in the final report…<\/p>\n<\/td>\n<\/tr>\n 10<\/p>\n<\/td>\n Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n 10.1<\/p>\n<\/td>\n Key Cross Competition<\/p>\n<\/td>\n<\/tr>\n 10.2<\/p>\n<\/td>\n VK2809: Viking Therapeutics<\/p>\n<\/td>\n<\/tr>\n 10.2.1<\/p>\n<\/td>\n Drug Description<\/p>\n<\/td>\n<\/tr>\n 10.2.2<\/p>\n<\/td>\n Others Developmental Activities<\/p>\n<\/td>\n<\/tr>\n 10.2.3<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n 10.2.4<\/p>\n<\/td>\n Safety and Efficacy<\/p>\n<\/td>\n<\/tr>\n 10.2.5<\/p>\n<\/td>\n Analyst’s View<\/p>\n<\/td>\n<\/tr>\n 10.3<\/p>\n<\/td>\n ALG-055009: Aligos Therapeutics\u00a0<\/p>\n<\/td>\n<\/tr>\n 10.4<\/p>\n<\/td>\n VK0214: Viking Therapeutics<\/p>\n<\/td>\n<\/tr>\n List of drugs to be continued in the final report…<\/p>\n<\/td>\n<\/tr>\n 11<\/p>\n<\/td>\n THR-\u03b2 Agonist: the 7MM Analysis<\/p>\n<\/td>\n<\/tr>\n 11.1<\/p>\n<\/td>\n Key Findings<\/p>\n<\/td>\n<\/tr>\n 11.2<\/p>\n<\/td>\n Key Market Forecast Assumptions<\/p>\n<\/td>\n<\/tr>\n 11.2.1<\/p>\n<\/td>\n Cost Assumptions and Rebates<\/p>\n<\/td>\n<\/tr>\n 11.2.2<\/p>\n<\/td>\n Pricing Trends<\/p>\n<\/td>\n<\/tr>\n 11.2.3<\/p>\n<\/td>\n Analogue Assessment<\/p>\n<\/td>\n<\/tr>\n 11.2.4<\/p>\n<\/td>\n Launch Year and Therapy Uptakes<\/p>\n<\/td>\n<\/tr>\n 11.3<\/p>\n<\/td>\n Market Outlook<\/p>\n<\/td>\n<\/tr>\n 11.4<\/p>\n<\/td>\n Attribute Analysis<\/p>\n<\/td>\n<\/tr>\n 11.5<\/p>\n<\/td>\n Total Market Size of THR-\u03b2 Agonist in the 7MM<\/p>\n<\/td>\n<\/tr>\n 11.6<\/p>\n<\/td>\n The US Market Size<\/p>\n<\/td>\n<\/tr>\n 11.6.1<\/p>\n<\/td>\n Total Market Size of THR-\u03b2 Agonist in the US<\/p>\n<\/td>\n<\/tr>\n 11.6.2<\/p>\n<\/td>\n Market Size of THR-\u03b2 Agonist by Therapies in the US<\/p>\n<\/td>\n<\/tr>\n 11.7<\/p>\n<\/td>\n EU4 and the UK Market Size<\/p>\n<\/td>\n<\/tr>\n 11.7.1<\/p>\n<\/td>\n Total Market Size of THR-\u03b2 Agonist in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 11.7.2<\/p>\n<\/td>\n Market Size of THR-\u03b2 Agonist by Therapies in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 11.8<\/p>\n<\/td>\n Japan Market Size<\/p>\n<\/td>\n<\/tr>\n 11.8.1<\/p>\n<\/td>\n Total Market Size of THR-\u03b2 Agonist in Japan<\/p>\n<\/td>\n<\/tr>\n 11.8.2<\/p>\n<\/td>\n Market Size of THR-\u03b2 Agonist by Therapies in Japan<\/p>\n<\/td>\n<\/tr>\n 12<\/p>\n<\/td>\n Unmet Needs<\/p>\n<\/td>\n<\/tr>\n 13<\/p>\n<\/td>\n SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n 14<\/p>\n<\/td>\n KOL Views<\/p>\n<\/td>\n<\/tr>\n 15<\/p>\n<\/td>\n Market Access and Reimbursement<\/p>\n<\/td>\n<\/tr>\n 15.1<\/p>\n<\/td>\n The US<\/p>\n<\/td>\n<\/tr>\n 15.2<\/p>\n<\/td>\n EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 15.3<\/p>\n<\/td>\n Japan<\/p>\n<\/td>\n<\/tr>\n 16<\/p>\n<\/td>\n Acronyms and Abbreviations<\/p>\n<\/td>\n<\/tr>\n 17<\/p>\n<\/td>\n Bibliography<\/p>\n<\/td>\n<\/tr>\n 18<\/p>\n<\/td>\n Report Methodology<\/p>\n<\/td>\n<\/tr>\n Related Reports<\/b><\/p>\n Metabolic Dysfunction-associated Steatohepatitis Market<\/a><\/b><\/p>\n Metabolic Dysfunction-associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies, including Inventiva Pharma, Novo Nordisk A\/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics,<\/b> among others.<\/p>\n Nonalcoholic Steatohepatitis Pipeline<\/a><\/b><\/p>\n Nonalcoholic Steatohepatitis Pipeline Insight <\/b>\u2013 2025<\/b>\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonalcoholic steatohepatitis\u00a0companies, including\u00a0Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, <\/b>among others.<\/p>\n Non-Alcoholic Fatty Liver Disease\u00a0Market<\/a><\/b><\/p>\n Non-Alcoholic Fatty Liver Disease<\/b> Market Insight, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key NAFLD companies, including\u00a0MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc.<\/b>, <\/b>among others.<\/p>\n X-linked Adrenoleukodystrophy Pipeline<\/a><\/b><\/p>\n X-linked Adrenoleukodystrophy<\/b> Market Insight, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key X-ALD companies, including\u00a0Minoryx Therapeutics, Viking Therapeutics, Poxel, Orpheris, Applied Genetic Technologies Corporation, NEURALGENE<\/b>, <\/b>among others.<\/p>\n About\u00a0DelveInsight<\/b><\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/b><\/p>\n Contact Us\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<\/b>Shruti Thakur
[email\u00a0protected]<\/a>
+14699457679<\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO40532&Transmission_Id=202507301746PR_NEWS_USPR_____IO40532&DateId=20250730\")
<\/p>\n","protected":false},"excerpt":{"rendered":"The THR\u2011\u03b2 agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such…\n","protected":false},"author":2,"featured_media":39492,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3091],"tags":[51,22427,22428,2441,16,15],"class_list":{"0":"post-305095","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-delveinsight-business-research","10":"tag-llp","11":"tag-markets","12":"tag-uk","13":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114944681323296903","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/305095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=305095"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/305095\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/39492"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=305095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=305095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=305095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}